CSIRO and Cicada Innovations to support building of an antimicrobial resistance industry.
Australia’s national science agency, CSIRO, has partnered with deep-tech incubator Cicada Innovations to deliver a free, online commercialisation course to help build an emerging industry of products and solutions to tackle antimicrobial resistance (AMR).
AMR occurs when disease-causing bacteria, fungi, and other germs no longer respond to medicines such as antibiotics. These drug-resistant ‘superbugs’ are on the rise globally and make infections harder to treat, increasing the risk of disease spread and severe illness and death in animals and humans.
There is an urgent need to address AMR and the clinical pipeline of new antimicrobials is dry. Currently, 700,000 people die each year from drug-resistant infections, and this is predicted to increase to up to 10 million deaths by 2050.
Dr Branwen Morgan who is leading CSIRO’s developing Antimicrobial Resistance Mission, said new drugs alone will not solve the issue.
“The drug pipeline is long and costly – we need innovative science, technology and engineering solutions to mitigate AMR now and into the future,” Dr Morgan said.
“Potential solutions could range from antimicrobial coatings to integrated sensors and software that identifies the presence of AMR to alternative treatments and diagnostics.”
“We have partnered with Cicada Innovations to offer the AMR Commercialisation 101 course, that will equip innovators with the knowledge and skills to commercialise new products that can make a significant impact in tackling this growing problem.”
The course is open to SMEs and researchers regardless of experience in AMR, from any sector where technologies could be adapted to solve AMR challenges.
Sally-Ann Williams, CEO of Cicada Innovations, said the new course will cover an introduction to the AMR landscape, commercialising medical technologies, introduction to lean start-up, idea and customer validation, and market analysis and competitive landscape.
“This course is a gateway for innovators looking to gain a foundational understanding of AMR and how to validate an idea and make an impact,” Ms Williams said.
“We’re calling on industry, SMEs and innovators to register for the free course and take the first step in translating their ideas into a solution which can save lives.”
AMR IS ONE OF THE GREATEST PUBLIC HEALTH AND BIOSECURITY THREATS FACING HUMANITY.
The course builds on Cicada Innovation’s successful medical technology commercialisation programs.
AMR Commercialisation 101 was launched today at the Antimicrobial Resistance Summit, a two-day event hosted by CSIRO in partnership with the Department of Health, the Department of Agriculture, Water and Environment and Department of Industry, Science and Resources.
The summit seeks to identify the innovative products, policies, and processes that could achieve the greatest impact on mitigating AMR in Australia.
The World Health Organization has declared AMR one of the top 10 global public health threats facing humanity. It is also a significant animal welfare and biosecurity issue.
Register for AMR Commercialisation 101: https://www.cicadainnovations.com/amr-commercialisation
Join CSIRO’s AMR Summit (17-18 November 2021): https://amr-summit-au.com/
AMR expert quotes:
Michelle Bonello PhD MPH, Hub Manager | ARC Industrial Transformation Research Hub - Antimicrobial Resistance, Kirby Institute, UNSW:
“An excellent introduction to AMR landscape. Everyone should have this information. The concepts presented in Research Impact and fundamentals to commercialisation was an eye opener.”
“The quizzes at the end of the module are a good way to check you have taken in the learnings. Overall, this is an excellent AMR Commercialisation tool that would be useful to a broad audience.”
Prof Trevor Lithgow, Director, Centre to Impact AMR, Monash University:
“This course would be excellent for pre-PhD students deciding between discovery-based versus applied/translational research training. It clearly delineates the distinct goals and value in research done where commercialization is the immediate goal.”
“The course structure lends itself equally to individuals, or to small student/trainee groups who could discuss their learnings together.”
Professor Tania Sorrell, AM, FAHMS | Professor and Co-Director, The University of Sydney Institute for Infectious Diseases:
“I think it [this course] is valuable for early career researchers and older researchers with a traditional academic background, i.e. those who have not been schooled in the lessons needed to successfully commercialise a product. It is easy to follow and interesting to listen to.”
Jane O'Dwyer, CEO, Cooperative Research Centres Association:
“The course is very professionally made with great content and provides an excellent introduction for any researcher thinking about leaping into commercialisation. The use of a peer-to-peer approach is very engaging too.”